The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.La presente descripción se refiere a métodos para el manejo del peso en un individuo con le necesidad del mismo al determinar el nivel de suficiencia renal del individuo y prescribir o administrar una cantidad terapéuticamente efectiva de (R)-8-cloro-1-metil-2, 3, 4, 5-tetrahidro-1H-3-benzazepina o una sal farmacéuticamente aceptable, solvato o hidrato del mismo al individuo, siempre que el individuo tenga un nivel de suficiencia renal seleccionado del grupo que consiste de: ningún daño renal, daño renal leve, y daño renal moderado. Además, la descripción se refiere a un método para seleccionar un individuo para el tratamiento con (R)-8-cloro-1-metil- 2, 3, 4, 5-tetrahidro-1 H-3-benzazepina o una sal farmacéuticamente aceptable, solvato o hidrato del mismo a
